Page last updated: 2024-12-06

cefodizime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5361871
CHEMBL ID2303613
CHEBI ID63214
SCHEMBL ID151101
MeSH IDM0103520

Synonyms (65)

Synonym
hr-221
diezime
modivid
cefodizime
timecef
thr-221
(6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefodizime (inn)
D07643
cdzm
cefodizime disodium
hr 221
cefodizime sodium [jan]
cefodizime [inn:ban]
(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(((5-(carboxymethyl)-4-methyl-2-thiazolyl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(z)-(o-methyloxime)
cefodizimum [inn-latin]
cefodizima [inn-spanish]
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefodizme
z31298j4hq ,
unii-z31298j4hq
ec 700-301-3
s 77 1221 b [as sodium]
thr 221 [as sodium]
hr 221 [as sodium]
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3-(((5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl)sulfanyl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefodizima
cefodizimum
7-{[(22z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-3,4-didehydrocepham-4-carboxylic acid
CHEBI:63214 ,
(6r,7r)-7-{[(22z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
thr 221 free acid
s 77 1221 b free acid
cefodizime [inn]
cefodizime [who-dd]
s-77-1221-b free acid
hr 221 free acid
thr-221 free acid
cefodizime [mi]
hr-221 free acid
S5235
s-77-1221b
hr-221 [as sodium]
CHEMBL2303613
thr 221
neucef
bdbm50422690
s-77-1221-b
thr-221 [as sodium]
s-771221b [as sodium]
s 77-1221b
SCHEMBL151101
J-700161
DTXSID2022757
(6r,7r)-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-7-{[(2z)-1-hydroxy-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefodizime acid
EX-A1379
HY-108402
CS-0028575
DB13470
mfcd00864926
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[5-(carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, (6r,7r)-
7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cef;cdz
AKOS040741529

Research Excerpts

Toxicity

Cefodizime sodium (THR-221) was studied in rats by comparing its toxic effect with those of other cephem antibiotics including cephaloridine (CER), cefazolin (CEZ) and cefmetazol (CMZ)

ExcerptReferenceRelevance
" Renal tolerance of CDZ proved to be better than that observed with other cephalosporins; furthermore, CDZ had no adverse effects on spermatogenesis, fertility or embryonic development."( Safety profile of cefodizime.
Andrassy, K, 1992
)
0.28
"Data from ten clinical trials involving 1189 patients treated with 1 g bd of cefodizime iv or im were analysed for adverse effects and abnormal laboratory test results."( Clinical safety profile of cefodizime.
Perianu, MR, 1990
)
0.28
" The LD50 values of THR-221 (mg/kg) were as follows: (1) mice: intravenous, 7200 for males and 5000 for females; intraperitoneal, 10500 for males and 11000 for females; subcutaneous, 17500 for males and 16500 for females; and oral, 28000 for males and 29000 for females."( [Acute toxicity study of cefodizime sodium].
Inazu, M; Kobayashi, T; Kuwata, M; Miyamoto, M; Morioka, H; Nakano, S; Sakaguchi, T; Wada, N; Yada, H, 1988
)
0.27
" Electron microscopically, no significant toxic changes were observed."( [Six-month chronic intravenous toxicity study of cefodizime sodium in dogs].
Kohda, S; Miura, K; Nakano, S; Narama, I; Nishikawa, H; Sano, M; Tsuchitani, M, 1988
)
0.27
" From the present results that no marked toxic signs were seen at any dose level, the toxicologically non-effective dose of THR-221 for rats of both sexes is considered to be more than 2000 mg/kg/day."( [One-month subacute intravenous toxicity study of cefodizime sodium in rats].
Abe, S; Inazu, M; Kobayashi, T; Miyamoto, M; Morioka, H; Sakaguchi, T; Yajima, R, 1988
)
0.27
"Nephrotoxicity of cefodizime sodium (THR-221), a new cephem antibiotic, was studied in rats by comparing its toxic effect with those of other cephem antibiotics including cephaloridine (CER), cefazolin (CEZ) and cefmetazol (CMZ)."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.27
" From these results, the non toxic effective dose level and the toxic dose level of THR-221 were estimated to be 500 mg/kg/day and more than 2000 mg/kg/day respectively, for male and female dogs."( [Five-week subacute intravenous toxicity study of cefodizime sodium in dogs].
Hirota, T; Irimura, K; Kurokawa, K; Morita, K; Nakano, S; Yada, H, 1988
)
0.27
" Mild adverse events occurred in only 3 patients (one per group)."( Open, controlled, randomized study on the efficacy and safety of cefodizime single daily dose versus two daily doses and versus ceftriaxone single daily dose in patients with acute purulent bronchitis and acute purulent exacerbation of chronic bronchitis.
Cocuzza, G; Zanussi, C, 1995
)
0.29

Pharmacokinetics

Cefodizime is a new aminothiazolyliminomethoxycephalosporin. The pharmacokinetic profile was evaluated in rabbits after intraduodenal administration with and without an absorption enhancer. Pharmacokinetic characteristics of cefadizime were assessed in 13 critically ill elderly patients.

ExcerptReferenceRelevance
" Furthermore, pharmacokinetic analysis of the data obtained from in vivo and in vitro experiments indicated that PCG reduced the permeability of [14C]CDZM across the sinusoidal and bile canalicular membranes to 32% and 40% of the control value, respectively."( Effect of benzylpenicillin on the disposition of cefodizime in rats: no net effect on total clearance due to decreased hepatobiliary clearance and increased renal clearance.
Hanano, M; Iga, T; Kawaguchi, Y; Matsushita, H; Sawada, Y; Sugiyama, Y; Suzuki, H, 1992
)
0.28
" The following pharmacokinetic indices were estimated after single and repeated (values in brackets) dosing: C0."( Pharmacokinetics of cefodizime in the elderly following single and repeated intravenous administration of 1 g.
Lenfant, B; Nilsen, OG; Rennemo, F; Rennemo, R, 1990
)
0.28
" Cefodizime concentrations in blood and urine (iv dosage only) sampled up to 12h post dose were measured by microbiological assay and pharmacokinetic parameters were derived on the basis of a two-compartment open model."( The pharmacokinetics of cefodizime in children.
Boccazzi, A; Careddu, P; Fusi, G; Maretti, M; Mezzopane, AM, 1990
)
0.28
" Based on these predicted pharmacokinetic parameters, we calculated the plasma concentration profiles of these drugs in humans and found a good agreement between the predicted and observed values."( Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals.
Hanano, M; Iga, T; Kawaguchi, Y; Matsushita, H; Sawada, Y; Sugiyama, Y; Suzuki, H, 1990
)
0.28
"We have conducted pharmacokinetic and clinical trials of a new cephem derivative, cefodizime (THR-221, CDZM), and obtained the following results."( [Pharmacokinetic and clinical studies on cefodizime in the field of obstetrics and gynecology].
Eguchi, K; Kondoh, T; Nakagiri, Y; Niida, K; Nishi, M; Okuda, H; Sanoh, T; Sekiba, K; Suzuki, Y; Yamashita, K, 1989
)
0.28
"The pharmacokinetic properties of cefodizime, a new aminothiazolyliminomethoxycephalosporin, were studied in laboratory animals and compared with the pharmacokinetics of another long-acting cephalosporin, ceftriaxone."( Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.
Klesel, N; Limbert, M; Schrinner, E; Seeger, K; Seibert, G; Winkler, I, 1984
)
0.27
"A physiologically based pharmacokinetic model was established to describe the hepatobiliary excretion process for ligands which are excreted into the bile without metabolic conversion."( Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion.
Hanano, M; Sathirakul, K; Sugiyama, Y; Suzuki, H; Yasuda, K, 1993
)
0.29
"5 liters), terminal elimination half-life (3."( Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.
Bryskier, A; Coussediere, D; Lenfant, B; Logeais, C; Namour, F; Rivault, O; Surjus, A, 1995
)
0.29
" The following pharmacokinetic parameters were calculated: maximum plasma concentration (C5 min), area under the plasma concentration-time curve (AUC), terminal half-life (T1/2), terminal rate constant (lambda-z), total clearance (Clt), volume of distribution (Vd), mean residence time (MRT), urine data-derived terminal half-life (T1/2 r), renal clearance (Clr)."( Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
Amorena, M; Calderaro, V; Contaldi, C; Lampa, E; Loffreda, A; Lucarelli, C; Rossi, F,
)
0.13
"The duration of time that serum levels are above the minimum inhibitory concentration (MIC; T >MIC) seems to be an important pharmacodynamic parameter for beta-lactams."( Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
Blandino, G; Milazzo, I; Musumeci, R; Nicoletti, G; Nicolosi, VM; Speciale, A, 2000
)
0.31
" The pharmacokinetic profile of cefodizime was evaluated in rabbits after intraduodenal administration with and without an absorption enhancer."( Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models.
Brandsch, M; Bretschneider, B; Härtl, A; Mrestani, Y; Neubert, RH, 2004
)
0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" Pharmacokinetic characteristics of cefodizime were assessed in 13 critically ill elderly patients (median age 73+/-6 years)."( Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
Bojic, A; Locker, G; Meyer, B; Schmid, R; Thalhammer, F; Traunmueller, F; Winkler, S, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The objective of this study was to evaluate whether pharmacokinetic parameters (clearance and volume of distribution of the central compartment) from a sparse sampling population pharmacokinetic study can be obtained with a very small sample size."( Population pharmacokinetics with a very small sample size.
Duan, J; Mahmood, I, 2009
)
0.35
"We developed a detailed, whole-body physiologically based pharmacokinetic (PBPK) modeling tool for calculating the distribution of pharmaceutical agents in the various tissues and organs of a human or animal as a function of time."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38

Compound-Compound Interactions

A study was done on cefodizime (THR-221, CDZM) in combination with ampicillin (ABPC) for its transferability to cerebrospinal fluid (CSF) of rabbits with experimental meningitis caused by Staphylococcus aureus. However, strains expressing class A beta-lactamase were susceptible to cefadizime in  combination with clavulanic acid.

ExcerptReferenceRelevance
"A study was done on cefodizime (THR-221, CDZM) in combination with ampicillin (ABPC) for its transferability to cerebrospinal fluid (CSF) of rabbits with experimental meningitis caused by Staphylococcus aureus."( [Experimental study on transferability to cerebrospinal fluid of cefodizime in combination with ampicillin].
Haruta, T; Kobayashi, Y; Okura, K, 1989
)
0.28
"In vivo synergistic effects of cefodizime (CDZM) were investigated in combination with aminoglycosides (AGs), sisomicin (SISO) or dibekacin (DKB) against Pseudomonas aeruginosa in immunocompromised tumour bearing mice."( [Therapeutic efficacy of cefodizime in combination with aminoglycosides against systemic infections caused by Pseudomonas aeruginosa in immunocompromised tumour bearing mice].
Deguchi, K; Furukawa, T; Hyodo, A; Miyake, Y; Uji, T, 1993
)
0.29
" However, strains expressing class A beta-lactamase were susceptible to cefodizime in combination with clavulanic acid."( In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors.
Amicosante, G; Franceschini, N; Oratore, A; Perilli, M; Segatore, B; Setacci, D, 1993
)
0.29
"The in vivo synergistic effect of cefodizime (CDZM) in combination with minocycline (MINO) against methicillin-resistant Staphylococcus aureus (MRSA) was investigated."( [Therapeutic efficacy of cefodizime in combination with minocycline against systemic infection caused by methicillin-resistant Staphylococcus aureus in immunocompromised tumour bearing mice].
Deguchi, K; Furukawa, T; Hyodo, A; Miyake, Y; Shimizu, C; Uji, T, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Concomitant administration of lidocaine did not alter either bioavailability or pharmacokinetic characteristics."( Pharmacokinetic profile of cefodizime.
Brockmeier, D; Dagrosa, EE, 1992
)
0.28
" The absolute bioavailability im is almost 100%."( Pharmacokinetics of cefodizime: a review of the data on file.
Barré, J, 1990
)
0.28
" Because of the obvious drawbacks of drug delivery by injection, the development of alternatives with enhanced oral bioavailability has received much attention in pharmaceutical research."( Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models.
Brandsch, M; Bretschneider, B; Härtl, A; Mrestani, Y; Neubert, RH, 2004
)
0.32
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
" Very low bioavailability (2."( Microemulsion and mixed micelle for oral administration as new drug formulations for highly hydrophilic drugs.
Behbood, L; Härtl, A; Mrestani, Y; Neubert, RH, 2010
)
0.36

Dosage Studied

Cefodizime 1 g IM once daily is an effective dosing regimen in the treatment of patients with community-acquired pneumonia.

ExcerptRelevanceReference
" The dosage of 1 x 2 g CDZ is recommended for the treatment of UUTI and complicated LUTI."( Cefodizime given once daily for the treatment of upper urinary tract infections and complicated lower urinary tract infections.
Hofstetter, AG, 1992
)
0.28
" No great differences were found between the clinical and microbiological results in the various dosage groups, and no corresponding improvement was noted with the highest dosages studied."( Clinical and bacteriological experience with cefodizime in acute purulent exacerbations of chronic bronchitis.
Costongs, RJ; Davies, BI; Geraedts, WH; Gubbelmans, HL; Maesen, FP; Meek, JC; van den Bergh, JJ, 1992
)
0.28
" No significant differences in clinical and bacteriological outcome were detected when the various CDZ dosage regimens were compared."( Review of effectiveness of cefodizime in the treatment of lower respiratory tract infections with parenchymal involvement.
Pauwels, RA, 1992
)
0.28
" It is concluded that a usual CDZ dosage regimen stimulates depressed phagocytosis in haemodialysis patients, and that this stimulatory effect persists for at least two weeks after the end of treatment."( Cefodizime: enhancement of depressed phagocytosis-associated respiratory burst activity in chronic uremic patients.
Ringoir, S; Vanholder, R, 1992
)
0.28
" A dosage regimen of 1 g every 12 h seems to be the most suitable schedule for the treatment of LRTI while 1 g every 12 h or 2 g every 24 h can equally well be adopted for treatment of UTI."( Cefodizime in clinical use: a review of the clinical trial reports.
Grassi, GG, 1990
)
0.28
" These results demonstrate a lack of accumulation and no changes in the pharmacokinetic profile of cefodizime during repeated dosing in the elderly."( Pharmacokinetics of cefodizime in the elderly following single and repeated intravenous administration of 1 g.
Lenfant, B; Nilsen, OG; Rennemo, F; Rennemo, R, 1990
)
0.28
" Cefodizime concentrations in blood and urine (iv dosage only) sampled up to 12h post dose were measured by microbiological assay and pharmacokinetic parameters were derived on the basis of a two-compartment open model."( The pharmacokinetics of cefodizime in children.
Boccazzi, A; Careddu, P; Fusi, G; Maretti, M; Mezzopane, AM, 1990
)
0.28
" The total clearance is about 20% less in elderly subjects than in young adults, but no dosing adjustment is needed in the elderly."( Pharmacokinetics of cefodizime: a review of the data on file.
Barré, J, 1990
)
0.28
" Mean dosage per application: 20."( [Experimental and clinical studies on cefodizime in pediatrics].
Aramaki, M; Kawakami, A; Koga, T; Motohiro, T; Oda, K; Okabayashi, S; Sakata, Y; Takajo, N; Tanaka, K; Yamashita, F, 1990
)
0.28
"2 micrograms/ml for 40 mg/kg, thus a dose-response was observed."( [Study on cefodizime, a new cephem antibiotic, in the field of pediatrics].
Matsumoto, K; Nakanishi, Y; Nakazawa, S; Narita, A; Niino, K; Sato, H; Suzuki, H, 1989
)
0.28
" Major changes in general conditions observed in mice and rats were decreased spontaneous activity, lying prone, respiratory changes, staggering gait, clonic or clonic-tonic convulsions, and cyanosis, and in the animals dosed orally, diarrhea or salivation was also noted."( [Acute toxicity study of cefodizime sodium].
Inazu, M; Kobayashi, T; Kuwata, M; Miyamoto, M; Morioka, H; Nakano, S; Sakaguchi, T; Wada, N; Yada, H, 1988
)
0.27
" The males were dosed for 9 weeks prior to mating and through the mating period, and the females were treated from 2 weeks before mating through day 6 of gestation."( [Fertility study of cefodizime sodium in mice--intravenous administration from pre-conceptional period through early period of gestation].
Akaike, M; Kitatani, T; Kobayashi, T; Takayama, K, 1988
)
0.27
" Each drug was administered single and consecutive 14-day dosage with its alone or in combination with either furosemide or gentamicin."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.27
" A linear response to dosage was shown (coefficient of correlation r = ."( Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
Dagrosa, EE; de Looze, S; Grötsch, H; Hajdú, P; Malerczyk, V; Seeger, K, 1987
)
0.27
" The dosage was 4 g/day, adapted to renal function as appropriate."( Hemostasis in patients with normal and impaired renal function under treatment with cefodizime.
Andrassy, K; Iwand, A; Jähnchen, E; Koderisch, J; Trenk, D, 1987
)
0.27
" We conclude that cefodizime 1 g IM once daily is an effective dosing regimen in the treatment of patients with community-acquired pneumonia."( Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group.
Canepa, G; Cantone, V; De Palma, M; Peri, A; Rocchi, D,
)
0.13
" In individuals with more severe renal impairment or those requiring chronic hemodialysis, dosage adjustment would be required."( Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
Conte, JE, 1994
)
0.29
"An in-vitro dialysis model was employed to assess the feasibility of once-daily dosing of cefodizime in the treatment of infections caused by various Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens, Providencia stuartii and Enterobacter cloacae."( Bactericidal activity of cefodizime on Enterobacteriaceae in an in-vitro model simulating plasma pharmacokinetics in humans.
Bryskier, A; Duez, JM; Kazmierczak, A; Neuwirth, C; Péchinot, A, 1997
)
0.3
" This novel information may be useful for the rational development of dosage schedules and may improve predictions regarding therapeutic outcome."( Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.
Agneter, E; Burgdorff, T; Eichler, HG; Georgopoulos, A; Haag, O; Jansen, B; Müller, M; Pehamberger, H; Stanek, G; Weninger, W, 1996
)
0.29
" Both drugs were administered twice at a dosage of 40 mg/kg of body weight (pre- and intraoperative)."( Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting.
Bartunek, A; Graninger, W; Hiesmayr, M; Parschalk, B; Pernerstorfer, T; Wenisch, C; Zedtwitz-Liebenstein, K, 1997
)
0.3
" Given a range of built-in features and its inherent flexibility to customization, the model can be used to study a variety of pharmacokinetic and pharmacodynamic problems such as the effects of inter-individual differences and disease-states on drug pharmacokinetics and pharmacodynamics, dosing optimization, and inter-species scaling."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
EC 1.14.18.1 (tyrosinase) inhibitorAny EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosinase (monophenol monooxygenase), EC 1.14.18.1, an enzyme that catalyses the oxidation of phenols (such as tyrosine) and is widespread in plants and animals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
1,3-thiazoles
oxime O-etherO-organyl oximes R2C=NOR' (R' =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki22,000.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki8,956.25490.79434.22108.0000AID612540
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki10.00000.84004.968210.0000AID681175
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki9,000.00003.00006.47788.5000AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681175TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:1
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID679813TP_TRANSPORTER: biliary excretion in SD rat1993The Journal of pharmacology and experimental therapeutics, Jun, Volume: 265, Issue:3
Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID679814TP_TRANSPORTER: biliary excretion in EHBR rat1993The Journal of pharmacology and experimental therapeutics, Jun, Volume: 265, Issue:3
Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (230)

TimeframeStudies, This Drug (%)All Drugs %
pre-199076 (33.04)18.7374
1990's121 (52.61)18.2507
2000's23 (10.00)29.6817
2010's8 (3.48)24.3611
2020's2 (0.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials38 (14.90%)5.53%
Reviews16 (6.27%)6.00%
Case Studies14 (5.49%)4.05%
Observational0 (0.00%)0.25%
Other187 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]